Senseonics Confirms Robust Q4 Growth with EU Greenlight and US AID Launch, Yet Transition Risks Loom

What happened

Senseonics reported fourth-quarter 2025 revenue of $14.3 million, a 72% year-over-year increase that aligns with preliminary figures and underscores strong demand for its Eversense 365 implantable CGM. The company secured CE Mark approval for Eversense 365 in Europe, a regulatory milestone that expands its commercial footprint but faces near-term execution hurdles with partner Ascensia. Additionally, it launched its first automated insulin delivery (AID) system integration with twiist in the US, enhancing technological differentiation though initial volumes are expected to be modest. These developments occur amid a critical shift to in-house U.S. commercialization, a move detailed in filings as high-risk due to ongoing cash burn and going-concern disclosures. While top-line momentum is evident, investors must scrutinize whether Senseonics can translate this growth into sustainable margins and funding stability without dilution.

Implication

Revenue growth validates Eversense 365's market appeal but does not address the core challenge of efficiently insourcing sales and marketing without escalating SG&A costs. CE Mark approval opens European opportunities, yet contributions will likely be limited initially and depend on Ascensia's execution, adding channel dependency. The AID integration with twiist supports long-term differentiation but is unlikely to materially impact 2026 financials, emphasizing that near-term performance hinges on U.S. commercialization. Persistent going-concern language and high cash burn necessitate close monitoring of financing actions, especially draws under the Hercules facility or potential equity raises that could dilute shareholders. Investors should await concrete evidence from 2026 quarterly results that Senseonics can hit its $58-62 million revenue and ~50% gross margin targets while extending its funding runway, aligning with the DeepValue report's 'WAIT' rating.

Thesis delta

The Q4 revenue confirmation and CE Mark approval reduce near-term uncertainty around growth and regulatory timelines, slightly bolstering the bullish narrative. However, the thesis remains unchanged: Senseonics' high execution risk, funding needs, and commercialization transition still dominate the investment case, reinforcing the 'WAIT' recommendation until 2026 performance demonstrates sustainable progress without dilutive financing.